Roivant Sciences (Roivant Sciences) Total Stockholders Equity : $5,968.6 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Total Stockholders Equity?

Roivant Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $5,968.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Roivant Sciences's Book Value per Share for the quarter that ended in Mar. 2024 was $7.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Roivant Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.08.

Roivant Sciences Total Stockholders Equity Historical Data

The historical data trend for Roivant Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Total Stockholders Equity Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Total Stockholders Equity

1,797.79

1,656.94

1,157.77

5,968.58

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial											1,157.77	910.73	948.53	6,089.76	5,968.58

Roivant Sciences (NAS:ROIV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Roivant Sciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5968.581	-	0)	/	805.846
	=	7.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Roivant Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(21.893	+	477.856)	/	5968.581
	=	0.08

Roivant Sciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000